Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous Complete Response (AxIn Study).

NCT05817903 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT05817903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05817903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous Complete Response (AxIn Study).
Lead sponsor
Consorzio Oncotech
Phase
Phase 2
Overall status
Recruiting
Start date
April 18, 2023
Completion date
April 1, 2027
Enrollment
118 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma